CUX1

Summary

CUX1 (cut like homeobox 1, HGNC:2557) is a protein-coding gene on chromosome 7q22.1, encoding Homeobox protein cut-like 1 (P39880). Transcription factor involved in the control of neuronal differentiation in the brain.

The protein encoded by this gene is a member of the homeodomain family of DNA binding proteins. It may regulate gene expression, morphogenesis, and differentiation and it may also play a role in the cell cycle progession. Several alternatively spliced transcript variants encoding different isoforms have been identified.

Source: NCBI Gene 1523 — RefSeq curated summary.

At a glance

• Gene–disease (curated): global developmental delay with or without impaired intellectual development (Definitive, GenCC) — +1 more curated relationship
• GWAS associations: 30
• Clinical variants (ClinVar): 627 total — 23 pathogenic, 29 likely-pathogenic
• Phenotypes (HPO): 27
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 7 cancer types
• Transcription factor: yes — 123 downstream targets (CollecTRI)
• MANE Select transcript: NM_181552

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2557
Approved symbol	CUX1
Name	cut like homeobox 1
Location	7q22.1
Locus type	gene with protein product
Status	Approved
Aliases	CDP, CDP1, CUX, CUT, Clox, CDP/Cut, CDP/Cux, Cux/CDP, CASP, GOLIM6
Ensembl gene	ENSG00000257923
Ensembl biotype	protein_coding
OMIM	116896
Entrez	1523

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 17 protein_coding, 4 retained_intron, 4 protein_coding_CDS_not_defined

ENST00000292535, ENST00000292538, ENST00000360264, ENST00000393824, ENST00000425244, ENST00000437600, ENST00000465461, ENST00000485792, ENST00000487284, ENST00000497815, ENST00000546411, ENST00000547394, ENST00000549414, ENST00000550008, ENST00000556210, ENST00000558469, ENST00000558836, ENST00000560541, ENST00000606749, ENST00000607092, ENST00000622516, ENST00000645010, ENST00000646649, ENST00000935679, ENST00000964683

RefSeq mRNA: 7 — MANE Select: NM_181552 NM_001202543, NM_001202544, NM_001202545, NM_001202546, NM_001913, NM_181500, NM_181552

CCDS: CCDS47672, CCDS56498, CCDS56499, CCDS56500, CCDS5720, CCDS5721, CCDS59071

Canonical transcript exons

ENST00000292535 — 24 exons

Exon	Start	End
ENSE00001332236	101817626	101817669
ENSE00001878777	102248412	102258233
ENSE00002332406	102234052	102234240
ENSE00002342371	102200071	102200172
ENSE00002345935	102227367	102227669
ENSE00002374551	102205114	102205170
ENSE00002376432	102239320	102239584
ENSE00002380308	102196634	102197305
ENSE00002405775	102198802	102198867
ENSE00002411234	102204391	102204556
ENSE00002420069	102201360	102202204
ENSE00003696300	102070339	102070417
ENSE00003696859	102178469	102178657
ENSE00003697509	102158560	102158608
ENSE00003698477	102193842	102193890
ENSE00003698759	102189813	102189871
ENSE00003698853	102104336	102104459
ENSE00003698992	101916115	101916225
ENSE00003699121	102115207	102115273
ENSE00003700196	102028098	102028145
ENSE00003700524	102170446	102170550
ENSE00003701391	102097364	102097501
ENSE00003701555	102111698	102111774
ENSE00003701853	102195507	102195603

Expression profiles

Bgee: expression breadth ubiquitous, 297 present calls, max score 98.72.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 70.2136 / max 1417.3582, expressed in 1822 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
80209	64.3762	1821
80208	4.5145	1522
80229	0.4964	227
80230	0.2835	126
80210	0.2719	107
80231	0.1744	91
80232	0.0387	10
80233	0.0205	7
80212	0.0097	3
80211	0.0096	4

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	98.72	gold quality
buccal mucosa cell	CL:0002336	96.78	gold quality
oocyte	CL:0000023	96.28	gold quality
stromal cell of endometrium	CL:0002255	96.03	gold quality
ganglionic eminence	UBERON:0004023	95.91	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.73	gold quality
cerebellar hemisphere	UBERON:0002245	95.65	gold quality
cerebellar cortex	UBERON:0002129	95.64	gold quality
right coronary artery	UBERON:0001625	95.63	gold quality
sural nerve	UBERON:0015488	95.56	gold quality
myometrium	UBERON:0001296	95.52	gold quality
body of uterus	UBERON:0009853	95.43	gold quality
cerebellum	UBERON:0002037	95.33	gold quality
apex of heart	UBERON:0002098	95.32	gold quality
primary visual cortex	UBERON:0002436	95.00	gold quality
smooth muscle tissue	UBERON:0001135	94.84	gold quality
right atrium auricular region	UBERON:0006631	94.76	gold quality
descending thoracic aorta	UBERON:0002345	94.75	gold quality
mucosa of stomach	UBERON:0001199	94.74	gold quality
ventricular zone	UBERON:0003053	94.68	gold quality
thoracic aorta	UBERON:0001515	94.67	gold quality
visceral pleura	UBERON:0002401	94.66	gold quality
ascending aorta	UBERON:0001496	94.65	gold quality
heart left ventricle	UBERON:0002084	94.58	gold quality
cardiac ventricle	UBERON:0002082	94.56	gold quality
cerebellar vermis	UBERON:0004720	94.54	gold quality
cardiac atrium	UBERON:0002081	94.49	gold quality
heart	UBERON:0000948	94.45	gold quality
coronary artery	UBERON:0001621	94.26	gold quality
left coronary artery	UBERON:0001626	94.24	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	12.29
E-MTAB-7249	no	3768.40
E-GEOD-100618	no	408.83

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

123 targets.

Target	Regulation
ABL1
ADAM2
AGTR1
AKT1
ARHGAP32	Repression
ARHGDIB	Activation
ATP11C
BCL2
BGLAP
CA9
CAV1
CCN5	Activation
CCNA2	Activation
CCND2
CCNE2	Activation
CD38
CD40
CD44
CD8A
CDH1	Repression
CDH13
CDH2	Activation
CDK2
CDKN1A	Unknown
CDKN1B	Unknown
CEBPE	Unknown
CEL
CFTR	Unknown
CHD4
CNTN2

JASPAR motifs

Motif	Name	Family
MA0754.1	CUX1	HD-CUT
MA0754.2	CUX1	HD-CUT
MA0754.3	CUX1	HD-CUT

JASPAR matrix evidence (PMIDs): PMID:7799919

Upstream regulators (CollecTRI, top): E2F1, E2F2, E2F3, E2F4

miRNA regulators (miRDB)

30 targeting CUX1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4489	99.50	65.56	785
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-6846-5P	98.81	65.86	1121
HSA-MIR-6848-5P	98.81	65.49	1126
HSA-MIR-4664-5P	98.17	65.07	1020
HSA-MIR-6819-5P	97.96	66.59	1071
HSA-MIR-637	97.91	64.05	1517
HSA-MIR-4665-5P	97.91	67.69	1536
HSA-MIR-4294	97.86	65.72	1110
HSA-MIR-6737-5P	97.75	66.54	1044
HSA-MIR-6812-5P	97.56	65.39	1059
HSA-MIR-6069	97.45	65.88	357
HSA-MIR-1291	96.28	65.89	1224
HSA-MIR-6835-5P	95.81	64.27	500
HSA-MIR-6775-3P	95.76	65.91	982

Literature-anchored findings (GeneRIF, showing 40)

• Transfection of keratinocytes with plasmid DNA leads to the loss of detectable DNA-binding activity of CCAAT displacement protein. (PMID:11953010)
• Analysis of flanking sequences of IgH and Ig kappa V region genes show extensive heterogeneity in frequency and location of CDP binding sites and capability of CDP to bind to the nuclear matrix. (PMID:12193717)
• Data report the characterization of a mammalian coiled-coil protein, CASP, a Golgi protein that shares with giantin a conserved histidine in its transmembrane domain. (PMID:12429822)
• Lack of LF expression in the acute promyelocytic leukemia cell line NB4 is associated with the persistent binding of the silencer CCAAT displacement protein (CDP/cut) to the LF promoter in these cells. (PMID:12522000)
• correlation between binding of CDP/Cux to the DNA pol alpha promoter and the stimulation of gene expression (PMID:12665598)
• CDP, in conjunction with one or more viral proteins, binds to the packaging sequences of Adenovirus type 5 to initiate the encapsidation process (PMID:12743282)
• our data suggested that somatic mutations in CDP gene were rare in unselected uterine leiomyomas (PMID:12766905)
• interaction of G9a with a sequence-specific transcription factor that regulates gene repression through CDP/cut. (PMID:15269344)
• CUTL1 plays a central role in coordinating a gene expression program associated with cell motility and tumor progression. (PMID:15950902)
• Binding of E2 at the binding sites play an important role in overcoming inhibition of E1 complex formation caused by the binding of CDP to the origin of replication. (PMID:16529788)
• PKA-induced phosphorylation results in decreased DNA binding affinity of CUTL1 and diminished CUTL1-mediated cell cycle progression and cell motility. (PMID:16574653)
• Single Nucleotide Polymorphism in CUTL1 is associated with myeloid neoplasias (PMID:17140660)
• CUTL1 transcriptionally up-regulates WNT5A on RNA, protein and promoter level. (PMID:17227781)
• Src plays a crucial role in CUTL1-induced tumor cell migration (PMID:17369846)
• CDP inhibits cytokine-induced NF-kappaB-regulated chemokine transcription in melanoma cells (PMID:17496784)
• CUX1 C-terminal proteolytic processing by a caspase enables transcriptional activation in proliferating cells (PMID:17681953)
• Data show that in renal cell carcinoma, the Cut-like homeodomain protein is involved in FIH-1 transcriptional regulation and is controlled by a specific signaling event involving protein kinase C zeta. (PMID:17682059)
• The data strongly suggest that CDP acts as a major suppressor for Human papillomavirus type 16 P670 transcription by binding to the promoter region in the undifferentiated cells (PMID:17957475)
• Genome-wide location analysis revealed that targets common to p110 CUX1 and E2F1 included many genes involved in cell cycle, DNA replication, and DNA repair. (PMID:18347061)
• This result revealed a negative feedback loop whereby CUX1 shuts down the expression of the protease that cleaves it. (PMID:18403643)
• CUX1 showed evidence of association with the HCMV major immediate early regulatory region and inhibited the capacity of the virus to express ie1 and ie2 transcripts, suggesting that this cellular factor regulates MIE gene expression following virus entry. (PMID:18614194)
• study reports that mitotic complex genes Ect2, RacGAP, and MKLP1 are coordinately induced in S phase in proliferating T lymphocytes as well as in epithelial cells, depending upon activity of the CUX1 and E2F1 transcription factors (PMID:19015243)
• Activation of non-canonical Wnt signaling pathway by EBV in epithelial cells suggests a novel mechanism of epithelial mesenchymal transition via CUX1 signaling. (PMID:19361498)
• role of p110 CUX1 in cell motility involves its functions in both activation and repression of transcription (PMID:19635798)
• data indicate that CUX1 represents an important survival factor downstream of PI3K/Akt, which orchestrates a transcriptional programme mediating resistance to apoptosis in pancreatic cancer. (PMID:20442202)
• GRIA3 plays a role as a mediator of tumor progression in pancreatic cancer downstream CUX1. (PMID:20689760)
• findings show that CUTL1 expression is gradually silenced at the posttranscriptional level during liver development; overexpression and knockdown studies that miR-122 repressed CUTL1 protein expression in HCC cell lines (PMID:20842632)
• Elevated levels of cux1 are associated with inflammatory bowel disease. (PMID:20848487)
• Transcriptional targets of CUX1 involved in DNA replication and bipolar mitosis defined a gene expression signature that, across 12 breast cancer gene expression datasets, was associated with poor clinical outcome. (PMID:21245318)
• we identified a novel CUX1-FGFR1 fusion oncogene in a patient with the 8p11 myeloproliferative syndrome and demonstrated its transforming potential in the Ba/F3 cell line. (PMID:21330321)
• modifications of CUX1 expression lead to aberrant expression of type I collagen, which may provide a molecular basis for fibrogenesis (PMID:21471005)
• screening for mutations in CUX1 using 15 secondary acute myeloid leukemia cases with preceding myeloproliferative neoplasms or loss-of-heterozygosity on chromosome 7q (collaborative study in several countries) (PMID:21674579)
• The data demonstrates that the autism spectrum disorder-associated A-C intronic haplotype of the ENGRAILED2 gene is a transcriptional activator, and both CUX1 and NFIB mediate this activity. (PMID:22180456)
• cux1 is associated with cell functions and human disease. (PMID:22306263)
• we find repression of apoptosis regulators by Cux1 in human cancer cells. (PMID:22438831)
• Our results provide the first evidence that polymorphisms of the CUX1 gene may be associated with response to antidepressant treatment in Japanese patients with MDD. (PMID:22584459)
• Authors found that both chromosomal inversions target the cut-like homeobox 1 (CUX1) gene on chromosomal band 7q22.1 in a way which is functionally equivalent to the more frequently observed del(7q) cases. (PMID:22965931)
• Cutl1 played transcriptional level mediated by signal transduction, translational level mediated by miR122, posttranslational level such as phosphorylation, de-phosphorylation, acetylation and proteolytic cleavage. (PMID:23085261)
• Data indicate CUX1 as a conserved, haploinsufficient tumor suppressor frequently deleted in myeloid neoplasms. (PMID:23212519)
• overexpression of active CUTL1 significantly resulted in increased cancer tissue response to chemotherapy and therefore inhibited growth, whereas knockdown of CUTL1 conferred resistance to chemotherapy. (PMID:23255599)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cux1a	ENSDARG00000078459
mus_musculus	Cux1	ENSMUSG00000029705
rattus_norvegicus	Cux1	ENSRNOG00000001424
drosophila_melanogaster	ct	FBGN0004198
caenorhabditis_elegans		WBGENE00000464

Paralogs (1): CUX2 (ENSG00000111249)

Protein

Protein identifiers

Homeobox protein cut-like 1 — P39880 (reviewed: P39880, Q13948)

Alternative names: CCAAT displacement protein, CDP/Cux p200, Homeobox protein cux-1

All UniProt accessions (5): P39880, Q13948, A0A2R8Y852, A0A2R8Y8D0, A0A2R8YDI1

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor involved in the control of neuronal differentiation in the brain. Regulates dendrite development and branching, and dendritic spine formation in cortical layers II-III. Also involved in the control of synaptogenesis. In addition, it has probably a broad role in mammalian development as a repressor of developmentally regulated gene expression. May act by preventing binding of positively-activing CCAAT factors to promoters. Component of nf-munr repressor; binds to the matrix attachment regions (MARs) (5’ and 3’) of the immunoglobulin heavy chain enhancer. Represses T-cell receptor (TCR) beta enhancer function by binding to MARbeta, an ATC-rich DNA sequence located upstream of the TCR beta enhancer. Binds to the TH enhancer; may require the basic helix-loop-helix protein TCF4 as a coactivator. Plays a role in cell cycle progression, in particular at the G1/S transition. As cells progress into S phase, a fraction of CUX1 molecules is proteolytically processed into N-terminally truncated proteins of 110 kDa. While CUX1 only transiently binds to DNA and carries the CCAAT-displacement activity, CDP/Cux p110 makes a stable interaction with DNA and stimulates expression of genes such as POLA1.

Subunit / interactions. Interacts with BANP. Interacts with SATB1 (via DNA-binding domains); the interaction inhibits the attachment of both proteins to DNA.

Subcellular location. Nucleus.

Post-translational modifications. Phosphorylated by PKA. As cells progress into S phase, a fraction of CUX1 molecules is proteolytically processed into N-terminally truncated proteins of 110 kDa by CTSL. Cell cycle-dependent processing of CUX1 serves to generate a CDP/Cux p110 with distinct DNA binding and transcriptional properties.

Disease relevance. Neurodevelopmental disorder with developmental delay and with or without motor or speech delay (NEDDMS) [MIM:618330] An autosomal dominant disorder characterized by global developmental delay associated with mild-to-moderate intellectual disability, hypotonia and short stature in some patients. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. Asn-1290 may participate in regulating DNA-binding activity by promoting homo- and heterodimerization.

Similarity. Belongs to the CUT homeobox family.

Isoforms (11)

UniProt ID	Names	Canonical?
P39880-1	1	yes
P39880-2	2
P39880-3	3
P39880-4	5
P39880-5	6
P39880-6	7
P39880-9	11
Q13948-1	4, CASP
Q13948-2	8
Q13948-9	9
Q13948-10	10

RefSeq proteins (7): NP_001189472, NP_001189473, NP_001189474, NP_001189475, NP_001904, NP_852477, NP_853530* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001356	HD	Domain
IPR003350	CUT_dom	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR010982	Lambda_DNA-bd_dom_sf	Homologous_superfamily
IPR017970	Homeobox_CS	Conserved_site
IPR057476	Cux_N	Domain
IPR012955	CASP_C	Domain

Pfam: PF00046, PF02376, PF08172, PF25398

UniProt features (85 total): compositionally biased region 16, sequence conflict 12, modified residue 11, splice variant 10, region of interest 9, sequence variant 5, DNA-binding region 4, cross-link 4, chain 3, coiled-coil region 3, site 2, topological domain 2, mutagenesis site 2, transmembrane region 1, helix 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
8WQF	ELECTRON MICROSCOPY	3.27
8WQE	ELECTRON MICROSCOPY	3.38
8WQI	ELECTRON MICROSCOPY	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P39880-F1	62.84	0.29
AF-Q13948-F1	83.04	0.52

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

P39880 (canonical)

Catalytic / active sites (2): 643–644 (cleavage; by ctsl); 747–755 (cleavage; by ctsl)

Post-translational modifications (14): 763, 909, 1059, 1069, 1270, 1337, 1455, 1486, 1496, 785, 811, 842, 1284, 540

Q13948

Post-translational modifications (1): 586

Mutagenesis-validated functional residues (2):

Position	Phenotype
624	retained in the endoplasmic reticulum.
629	no effect on subcellular location.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants
R-HSA-5655302	Signaling by FGFR1 in disease
R-HSA-6811438	Intra-Golgi traffic
R-HSA-199991	Membrane Trafficking
R-HSA-5653656	Vesicle-mediated transport
R-HSA-6811442	Intra-Golgi and retrograde Golgi-to-ER traffic

MSigDB gene sets: 451 (showing top): GOBP_DENDRITE_DEVELOPMENT, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, TTTGTAG_MIR520D, GOBP_REGULATION_OF_DENDRITE_MORPHOGENESIS, NIKOLSKY_OVERCONNECTED_IN_BREAST_CANCER, MORF_RAD21, GOBP_NEUROGENESIS, MEF2_02, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, REACTOME_MEMBRANE_TRAFFICKING, GOBP_POSITIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, HUMMERICH_SKIN_CANCER_PROGRESSION_DN, GOBP_INTRA_GOLGI_VESICLE_MEDIATED_TRANSPORT, MARTINEZ_RB1_TARGETS_UP

GO Biological Process (5): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of dendrite morphogenesis (GO:0050775), intra-Golgi vesicle-mediated transport (GO:0006891), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (5): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), sequence-specific DNA binding (GO:0043565), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677)

GO Cellular Component (7): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), Golgi apparatus (GO:0005794), cytosol (GO:0005829), Golgi membrane (GO:0000139), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
FGFR1 mutant receptor activation	1
Signaling by FGFR in disease	1
Intra-Golgi and retrograde Golgi-to-ER traffic	1
Vesicle-mediated transport	1
Membrane Trafficking	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
intracellular membrane-bounded organelle	2
cytoplasm	2
negative regulation of DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of cell morphogenesis	1
positive regulation of cell projection organization	1
dendrite morphogenesis	1
regulation of dendrite morphogenesis	1
positive regulation of neurogenesis	1
Golgi vesicle transport	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription cis-regulatory region binding	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
DNA binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
chromosome	1
nuclear lumen	1
endomembrane system	1
Golgi apparatus	1
bounding membrane of organelle	1

Protein interactions and networks

STRING

1966 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CUX1	TBR1	Q16650	849
CUX1	EWSR1	Q01844	832
CUX1	BCL11B	Q9C0K0	819
CUX1	EOMES	O95936	781
CUX1	GOLGA5	Q8TBA6	778
CUX1	SPP2	Q13103	772
CUX1	CCNA2	P20248	770
CUX1	CCNA1	P78396	763
CUX1	SATB2	Q9UPW6	753
CUX1	BANP	Q8N9N5	741
CUX1	FOXP2	O15409	656
CUX1	PAX6	P26367	646
CUX1	RB1	P06400	644
CUX1	EMX1	Q04741	615
CUX1	GOLGB1	Q14789	610

IntAct

124 interactions, top by confidence:

A	B	Type	Score
RNF146	TNKS	psi-mi:“MI:0914”(association)	0.790
RB1	CUX1	psi-mi:“MI:0403”(colocalization)	0.610
RB1	CUX1	psi-mi:“MI:0915”(physical association)	0.610
CUX1	RB1	psi-mi:“MI:0915”(physical association)	0.610
CUX1	RB1	psi-mi:“MI:0407”(direct interaction)	0.610
CXCR4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
C3AR1	TMEM120B	psi-mi:“MI:0914”(association)	0.530
MAGEA10	POTEF	psi-mi:“MI:0914”(association)	0.530
KXD1	HIP1	psi-mi:“MI:0914”(association)	0.530
WDR83	SH2B2	psi-mi:“MI:0914”(association)	0.530
NUP62	RGPD8	psi-mi:“MI:0914”(association)	0.530
NDUFB8	NDUFS4	psi-mi:“MI:0914”(association)	0.530
LAMP1	FZD7	psi-mi:“MI:0914”(association)	0.530
RAB30	UBB	psi-mi:“MI:0914”(association)	0.530
B4GAT1	ADCY6	psi-mi:“MI:0914”(association)	0.530
CHRNA4	FZD6	psi-mi:“MI:0914”(association)	0.530
CSGALNACT2	TPST1	psi-mi:“MI:0914”(association)	0.530
GPRC5B	STXBP3	psi-mi:“MI:0914”(association)	0.530
SLC30A2	ESYT2	psi-mi:“MI:0914”(association)	0.530
FMR1	ACOT7	psi-mi:“MI:0914”(association)	0.500
EN1	NFIB	psi-mi:“MI:2364”(proximity)	0.470
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
CUX1	KRT8	psi-mi:“MI:0915”(physical association)	0.400
FOXE1	DDX39A	psi-mi:“MI:0914”(association)	0.350
FOXG1	DDX39A	psi-mi:“MI:0914”(association)	0.350
FOXJ2	TCERG1	psi-mi:“MI:0914”(association)	0.350

BioGRID (266): CUX1 (Reconstituted Complex), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), CUX1 (Co-fractionation), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS)

ESM2 similar proteins: A0JNT9, A0JPP8, A1X157, O15169, O75145, O75335, P39880, P60469, Q07DZ5, Q08CF3, Q08E13, Q09YM8, Q2M1P5, Q2QLG9, Q2VUH7, Q32PN7, Q3TMW1, Q3UHC7, Q3UIL6, Q3UIW5, Q3UJV1, Q5DU25, Q5FWS6, Q5JU85, Q5PRF9, Q5XI59, Q5ZJ07, Q674X7, Q68UI8, Q69ZS8, Q6IPM2, Q6NZT2, Q6P402, Q6P730, Q6ZP65, Q80XS6, Q80Y83, Q8JZP9, Q8K1S6, Q8R4R9

Diamond homologs: O08755, O14529, O95948, P34237, P39880, P39881, P53564, P53565, P70298, P70403, P70512, Q13948, Q5R8V1, Q6XBJ3, Q9NJB5, Q9UBC0, A1YEY5, A1YFI3, A1YG57, A2T733, A2T7P4, O15499, O35652, P09082, P0CJ85, P0CJ86, P0CJ87, P0CJ88, P0CJ89, P0CJ90, P10180, P29454, P37934, P37935, P37936, P53544, P53545, P53546, P55813, P56915

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CDK1	down-regulates	CUX1	phosphorylation
CUX1	“down-regulates quantity by repression”	PIK3IP1	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 169 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Deactivation of the beta-catenin transactivating complex	7	13.6×	3e-04
TCF dependent signaling in response to WNT	9	8.8×	3e-04

GO biological processes:

GO term	Partners	Fold	FDR
hair follicle development	5	12.2×	7e-03
chondrocyte differentiation	6	11.5×	3e-03
canonical Wnt signaling pathway	7	6.8×	8e-03
brain development	10	5.1×	5e-03
transcription by RNA polymerase II	10	4.5×	8e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 7 cancer types — BRCA, GB, LUAD, LUSC, MEL, PAAD, WDTC.

Clinical variants and AI predictions

ClinVar

627 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	23
Likely pathogenic	29
Uncertain significance	357
Likely benign	115
Benign	24

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1064787	NM_181552.4(CUX1):c.1687C>T (p.Gln563Ter)	Pathogenic
1213753	NM_181552.4(CUX1):c.1834C>T (p.Gln612Ter)	Pathogenic
1676077	NM_001913.5(CUX1):c.1855_1856del (p.Thr619fs)	Pathogenic
1803930	NM_181552.4(CUX1):c.190-2A>G	Pathogenic
1803932	NM_181552.4(CUX1):c.3563G>A (p.Trp1188Ter)	Pathogenic
1803938	NM_181552.4(CUX1):c.538C>T (p.Gln180Ter)	Pathogenic
1803942	NM_181552.4(CUX1):c.1593del (p.Met532fs)	Pathogenic
1804166	t(7;10)(q22.1;q26.3)	Pathogenic
1805954	NM_181552.4(CUX1):c.875T>A (p.Leu292Ter)	Pathogenic
1809898	NM_181552.4(CUX1):c.3721C>T (p.Gln1241Ter)	Pathogenic
2691892	NM_181552.4(CUX1):c.3556C>T (p.Gln1186Ter)	Pathogenic
3254744	NM_181552.4(CUX1):c.2053C>T (p.Gln685Ter)	Pathogenic
3257575	GRCh37/hg19 7q22.1(chr7:101639800-101926382)x1	Pathogenic
3270347	NM_181552.4(CUX1):c.1297C>T (p.Gln433Ter)	Pathogenic
3366947	NM_181552.4(CUX1):c.1289dup (p.Pro431fs)	Pathogenic
3382169	NM_181552.4(CUX1):c.3201del (p.Lys1068fs)	Pathogenic
3498727	NM_181552.4(CUX1):c.346C>T (p.Gln116Ter)	Pathogenic
3837504	NM_181552.4(CUX1):c.1289del (p.Pro430fs)	Pathogenic
4008410	NM_001202543.1:c.3655+190_*301del	Pathogenic
4532046	NM_181552.4(CUX1):c.466C>T (p.Gln156Ter)	Pathogenic
4532047	NM_181552.4(CUX1):c.2950C>T (p.Arg984Ter)	Pathogenic
618994	NC_000007.13:g.(101759560_?)_(?_101893297)del	Pathogenic
985065	NM_181552.4(CUX1):c.1558C>T (p.Gln520Ter)	Pathogenic
1324196	NM_181552.4(CUX1):c.530+1G>A	Likely pathogenic
1690336	NM_181552.4(CUX1):c.2986C>T (p.Arg996Ter)	Likely pathogenic
1710422	NM_001913.5(CUX1):c.1813dup (p.Leu605fs)	Likely pathogenic
1803931	NM_181552.4(CUX1):c.3500_3503del (p.Arg1167fs)	Likely pathogenic
1803934	NM_181552.4(CUX1):c.3786del (p.Tyr1263fs)	Likely pathogenic
1803939	NM_181552.4(CUX1):c.762G>C (p.Arg254Ser)	Likely pathogenic
1803940	NM_181552.4(CUX1):c.952G>T (p.Glu318Ter)	Likely pathogenic

SpliceAI

6411 predictions. Top by Δscore:

Variant	Effect	Δscore
7:101817670:G:C	donor_loss	1.0000
7:101916101:T:TA	acceptor_gain	1.0000
7:101916110:A:AG	acceptor_gain	1.0000
7:101916111:ACAG:A	acceptor_gain	1.0000
7:101916112:CAG:C	acceptor_gain	1.0000
7:101916112:CAGA:C	acceptor_loss	1.0000
7:101916112:CAGAG:C	acceptor_gain	1.0000
7:101916113:A:AG	acceptor_gain	1.0000
7:101916113:A:C	acceptor_loss	1.0000
7:101916113:AGA:A	acceptor_gain	1.0000
7:101916113:AGAGA:A	acceptor_gain	1.0000
7:101916114:G:GC	acceptor_gain	1.0000
7:101916114:G:T	acceptor_gain	1.0000
7:101916114:GA:G	acceptor_gain	1.0000
7:101916114:GAGA:G	acceptor_gain	1.0000
7:101916114:GAGAG:G	acceptor_gain	1.0000
7:101916221:CAGAG:C	donor_loss	1.0000
7:101916222:AGAGG:A	donor_loss	1.0000
7:101916223:GAG:G	donor_gain	1.0000
7:101916224:AGG:A	donor_loss	1.0000
7:101916225:GG:G	donor_loss	1.0000
7:101916226:GT:G	donor_loss	1.0000
7:101916227:T:A	donor_loss	1.0000
7:102028062:A:AG	acceptor_gain	1.0000
7:102028062:AAAT:A	acceptor_gain	1.0000
7:102028062:AAATG:A	acceptor_gain	1.0000
7:102028063:A:AG	acceptor_gain	1.0000
7:102028063:AAT:A	acceptor_gain	1.0000
7:102028063:AATG:A	acceptor_gain	1.0000
7:102028064:A:G	acceptor_gain	1.0000

AlphaMissense

9803 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:101916185:T:C	L34P	1.000
7:101916206:T:C	F41S	1.000
7:101916210:G:C	K42N	1.000
7:101916210:G:T	K42N	1.000
7:102028126:T:C	L57P	1.000
7:102070349:T:C	L67P	1.000
7:102070369:G:C	A74P	1.000
7:102070382:T:C	F78S	1.000
7:102097448:T:C	L118P	1.000
7:102097460:T:C	L122P	1.000
7:102104345:T:A	I139K	1.000
7:102104354:T:C	L142P	1.000
7:102115240:T:C	L214P	1.000
7:102158592:T:C	L236P	1.000
7:102158600:G:C	A239P	1.000
7:102170449:G:C	A243P	1.000
7:102189817:T:C	L341P	1.000
7:102197081:C:A	A557D	1.000
7:102197090:T:A	V560D	1.000
7:102197093:A:T	K561I	1.000
7:102197094:A:C	K561N	1.000
7:102197094:A:T	K561N	1.000
7:102197102:T:A	L564Q	1.000
7:102197102:T:C	L564P	1.000
7:102197102:T:G	L564R	1.000
7:102197111:A:C	H567P	1.000
7:102197117:T:A	I569N	1.000
7:102197119:G:A	G570R	1.000
7:102197119:G:C	G570R	1.000
7:102197120:G:A	G570E	1.000

dbSNP variants (sampled 300 via entrez): RS1000007831 (7:101951930 G>A), RS1000010221 (7:101996169 G>T), RS1000049436 (7:102212354 C>T), RS1000051880 (7:102262073 C>A), RS1000054437 (7:101837142 A>T), RS1000059114 (7:101878608 A>G), RS1000059323 (7:101951600 G>A,T), RS1000071967 (7:102071037 C>A,G), RS1000093720 (7:102109523 C>G,T), RS1000105639 (7:101876505 G>A), RS1000109387 (7:102182927 G>A), RS1000110664 (7:102153400 C>T), RS1000114005 (7:102252439 C>A), RS1000117200 (7:101834028 C>T), RS1000118900 (7:101990301 G>A,T)

Disease associations

OMIM: gene MIM:116896 | disease phenotypes: MIM:618330, MIM:126800, MIM:608636

GenCC curated gene-disease

Disease	Classification	Inheritance
global developmental delay with or without impaired intellectual development	Definitive	Autosomal dominant
autosomal dominant non-syndromic intellectual disability	Supportive	Autosomal dominant

Mondo (7): global developmental delay with or without impaired intellectual development (MONDO:0032680), neurodevelopmental disorder (MONDO:0700092), Duane retraction syndrome (MONDO:0007473), myeloproliferative neoplasm (MONDO:0020076), 15q11q13 microduplication syndrome (MONDO:0012081), intellectual disability (MONDO:0001071), autosomal dominant non-syndromic intellectual disability (MONDO:0015802)

Orphanet (4): Duane retraction syndrome (Orphanet:233), Myeloproliferative neoplasm (Orphanet:98274), 15q11q13 microduplication syndrome (Orphanet:238446), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

27 total (27 of 27 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000047	Hypospadias
HP:0000219	Thin upper lip vermilion
HP:0000276	Long face
HP:0000337	Broad forehead
HP:0000369	Low-set ears
HP:0000414	Bulbous nose
HP:0000601	Hypotelorism
HP:0000637	Long palpebral fissure
HP:0000677	Oligodontia
HP:0000750	Delayed speech and language development
HP:0000767	Pectus excavatum
HP:0001249	Intellectual disability
HP:0001252	Hypotonia
HP:0001263	Global developmental delay
HP:0001270	Motor delay
HP:0001357	Plagiocephaly
HP:0001629	Ventricular septal defect
HP:0001631	Atrial septal defect
HP:0001643	Patent ductus arteriosus
HP:0002007	Frontal bossing
HP:0003593	Infantile onset
HP:0004322	Short stature
HP:0006956	Lateral ventricle dilatation
HP:0007010	Poor fine motor coordination
HP:0012704	Widened subarachnoid space
HP:0100632	Pulmonary sequestration

GWAS associations

30 associations (top):

Study	Trait	p-value
GCST001528_1	Response to antidepressants	2.000000e-06
GCST003657_7	Attention deficit hyperactivity disorder symptom score	7.000000e-06
GCST003726_24	Basal cell carcinoma	2.000000e-13
GCST004599_54	Mean platelet volume	2.000000e-32
GCST004599_55	Mean platelet volume	1.000000e-09
GCST004607_157	Plateletcrit	4.000000e-12
GCST004616_188	Platelet distribution width	7.000000e-34
GCST004619_28	Reticulocyte fraction of red cells	2.000000e-09
GCST004622_5	Reticulocyte count	2.000000e-09
GCST004988_663	Breast cancer	5.000000e-12
GCST005316_8	Intelligence (MTAG)	3.000000e-09
GCST007565_30	Morning person	5.000000e-14
GCST007576_426	Chronotype	5.000000e-14
GCST008870_66	Keratinocyte cancer (MTAG)	3.000000e-19
GCST008871_61	Basal cell carcinoma	1.000000e-24
GCST009203_4	Cerebellum cortex volume	3.000000e-06
GCST009724_11	Vertical cup-disc ratio (multi-trait analysis)	7.000000e-10
GCST010242_236	HDL cholesterol levels	1.000000e-08
GCST90002381_457	Eosinophil count	1.000000e-13
GCST90002382_157	Eosinophil percentage of white cells	1.000000e-11
GCST90002385_146	High light scatter reticulocyte count	1.000000e-09
GCST90002386_457	High light scatter reticulocyte percentage of red cells	9.000000e-10
GCST90002395_694	Mean platelet volume	1.000000e-66
GCST90002395_695	Mean platelet volume	1.000000e-17
GCST90002400_45	Plateletcrit	3.000000e-46
GCST90002400_46	Plateletcrit	7.000000e-10
GCST90002401_463	Platelet distribution width	3.000000e-70
GCST90002405_486	Reticulocyte count	3.000000e-18
GCST90002406_254	Reticulocyte fraction of red cells	4.000000e-17
GCST90013410_8	Basal cell carcinoma	5.000000e-17

EFO canonical traits (11, from GWAS)

EFO ID	Trait name
EFO:0007860	ADHD symptom measurement
EFO:0007985	platelet crit
EFO:0007984	platelet component distribution width
EFO:0007986	reticulocyte count
EFO:0004337	intelligence
EFO:0008328	chronotype measurement
EFO:0010176	keratinocyte carcinoma
EFO:0006939	cup-to-disc ratio measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004842	eosinophil count
EFO:0007991	eosinophil percentage of leukocytes

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D004370	Duane Retraction Syndrome	C10.292.562.700.375.500; C11.270.235; C11.590.436.400.500; C16.320.290.235
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs201522	CUX1		0.00	0
rs365836	CUX1		0.00	0

CTD chemical–gene interactions

66 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression, affects expression	3
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	3
bisphenol A	decreases expression, decreases methylation	2
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
Arsenic	affects methylation, affects cotreatment, decreases expression, increases abundance	2
Benzo(a)pyrene	decreases expression	2
Hydrogen Peroxide	decreases expression, increases expression	2
Tobacco Smoke Pollution	increases methylation	2
Valproic Acid	decreases expression, increases methylation	2
Aflatoxin B1	decreases methylation, increases methylation	2
Cadmium Chloride	increases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, increases methylation	1
TAK-243	decreases sumoylation	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
glycidyl methacrylate	decreases expression	1
pyrimidin-2-one beta-ribofuranoside	decreases expression	1
decabromobiphenyl ether	decreases expression	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
tetrabromobisphenol A	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
benzo(e)pyrene	decreases methylation	1
4-hydroxy-2-nonenal	decreases expression	1
aflatoxin B2	affects methylation	1
coumarin	affects phosphorylation	1

Cellosaurus cell lines

4 cell lines: 3 embryonic stem cell, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A0V3	SEES3-1V human CUX1, clone1	Embryonic stem cell	Male
CVCL_A0V4	SEES3-1V human CUX1, clone2	Embryonic stem cell	Male
CVCL_A0V5	SEES3-1V human CUX1, clone3	Embryonic stem cell	Male
CVCL_GZ78	K562 eGFP-CUX1	Cancer cell line	Female

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice